AC   CVCL_0013
SY   Molt-4; MOLT 4; Molt 4; MOLT.4; MOLT4; Molt4; GM02219; GM02219C; GM2219C; GM02219D
DR   BTO; BTO:0000873
DR   CLO; CLO_0007825
DR   CLO; CLO_0032246
DR   CLO; CLO_0050992
DR   EFO; EFO_0001220
DR   MCCL; MCC:0000335
DR   CLDB; cl3524
DR   CLDB; cl3525
DR   CLDB; cl3527
DR   CLDB; cl3528
DR   CLDB; cl3529
DR   CLDB; cl3530
DR   CLDB; cl3531
DR   CLDB; cl3532
DR   CLDB; cl4976
DR   CLDB; cl5233
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-1582
DR   BCRC; 60060
DR   BCRJ; 0176
DR   BioSample; SAMN03470847
DR   BioSample; SAMN03471400
DR   BioSample; SAMN03472410
DR   BioSample; SAMN03473319
DR   BioSample; SAMN10988202
DR   cancercelllines; CVCL_0013
DR   CCRID; 1101HUM-PUMC000043
DR   CCRID; 3101HUMTCHu224
DR   CCRID; 4201HUM-CCTCC00083
DR   Cell_Model_Passport; SIDM00145
DR   ChEMBL-Cells; CHEMBL3307557
DR   ChEMBL-Targets; CHEMBL614177
DR   CLS; 300115
DR   Coriell; GM02219
DR   Cosmic; 716176
DR   Cosmic; 721716
DR   Cosmic; 801730
DR   Cosmic; 850194
DR   Cosmic; 850381
DR   Cosmic; 875865
DR   Cosmic; 897451
DR   Cosmic; 905958
DR   Cosmic; 913409
DR   Cosmic; 919154
DR   Cosmic; 922677
DR   Cosmic; 932766
DR   Cosmic; 933547
DR   Cosmic; 974249
DR   Cosmic; 991545
DR   Cosmic; 999763
DR   Cosmic; 1012099
DR   Cosmic; 1019314
DR   Cosmic; 1044254
DR   Cosmic; 1070704
DR   Cosmic; 1071877
DR   Cosmic; 1082518
DR   Cosmic; 1092615
DR   Cosmic; 1115596
DR   Cosmic; 1118467
DR   Cosmic; 1127263
DR   Cosmic; 1130237
DR   Cosmic; 1151788
DR   Cosmic; 1175131
DR   Cosmic; 1175857
DR   Cosmic; 1176596
DR   Cosmic; 1226858
DR   Cosmic; 1305339
DR   Cosmic; 1312325
DR   Cosmic; 1330500
DR   Cosmic; 1483362
DR   Cosmic; 1509200
DR   Cosmic; 1524808
DR   Cosmic; 1639636
DR   Cosmic; 1664513
DR   Cosmic; 1811158
DR   Cosmic; 1998457
DR   Cosmic; 2039521
DR   Cosmic; 2165720
DR   Cosmic; 2361368
DR   Cosmic; 2602924
DR   Cosmic; 2560251
DR   Cosmic-CLP; 905958
DR   dbMHC; 48976
DR   DepMap; ACH-001127
DR   DSMZ; ACC-362
DR   DSMZCellDive; ACC-362
DR   ECACC; 85011413
DR   ECACC; 94022544
DR   EGA; EGAS00001000978
DR   GDSC; 905958
DR   GEO; GSM2092
DR   GEO; GSM50196
DR   GEO; GSM50912
DR   GEO; GSM236794
DR   GEO; GSM236830
DR   GEO; GSM743460
DR   GEO; GSM750821
DR   GEO; GSM799348
DR   GEO; GSM799411
DR   GEO; GSM887336
DR   GEO; GSM888412
DR   GEO; GSM1178423
DR   GEO; GSM1178424
DR   GEO; GSM1178425
DR   GEO; GSM1181333
DR   GEO; GSM1181349
DR   GEO; GSM1670128
DR   GEO; GSM1696583
DR   GEO; GSM1696584
DR   GEO; GSM1696585
DR   GEO; GSM1696586
DR   GEO; GSM2124644
DR   GEO; GSM4471876
DR   GEO; GSM5137731
DR   IARC_TP53; 27042
DR   ICLC; HTL99025
DR   IHW; IHW09226
DR   IPD-IMGT/HLA; 11094
DR   JCRB; IFO50362
DR   KCB; KCB 200940YJ
DR   KCLB; 21582
DR   Lonza; 810
DR   NCBI_Iran; C149
DR   PharmacoDB; MOLT4_958_2019
DR   PRIDE; PXD005942
DR   PRIDE; PXD005946
DR   PRIDE; PXD018565
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0013
DR   PubChem_Cell_line; CVCL_0013
DR   RCB; RCB0206
DR   Ubigene; YC-C127
DR   Wikidata; Q54906365
RX   CelloPub=CLPUB00447;
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   DOI=10.11418/jtca1981.15.4_211;
RX   DOI=10.4172/2157-7145.S2-005;
RX   PubMed=165156;
RX   PubMed=1765142;
RX   PubMed=2041050;
RX   PubMed=2140233;
RX   PubMed=2144611;
RX   PubMed=2846092;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3335022;
RX   PubMed=3874327;
RX   PubMed=4547172;
RX   PubMed=4567231;
RX   PubMed=6181032;
RX   PubMed=6198871;
RX   PubMed=6200433;
RX   PubMed=6582512;
RX   PubMed=6954533;
RX   PubMed=8127147;
RX   PubMed=8316623;
RX   PubMed=8547074;
RX   PubMed=8558913;
RX   PubMed=8641406;
RX   PubMed=8957066;
RX   PubMed=9510473;
RX   PubMed=9685479;
RX   PubMed=9787181;
RX   PubMed=10071127;
RX   PubMed=10700174;
RX   PubMed=10739008;
RX   PubMed=11021758;
RX   PubMed=11226526;
RX   PubMed=11416159;
RX   PubMed=11986953;
RX   PubMed=12068308;
RX   PubMed=15472075;
RX   PubMed=15748285;
RX   PubMed=15901131;
RX   PubMed=16408098;
RX   PubMed=17088437;
RX   PubMed=17117183;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20922763;
RX   PubMed=22068913;
RX   PubMed=22347499;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=24762992;
RX   PubMed=25877200;
RX   PubMed=26295583;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28196595;
RX   PubMed=28569787;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=32449352;
RX   PubMed=35354797;
RX   PubMed=35839778;
CC   Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Part of: NCI-60 cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 31.56 +- 1.49 hours (PubMed=24762992); 33 hours (PubMed=17117183); 29 hours (PubMed=20922763); 24-48 hours (CLS=300115); ~40 hours (DSMZ=ACC-362); 27.9 hours (NCI-DTP=MOLT-4).
CC   HLA typing: A*01:01:01,25:01; B*18,57:01:01; C*06:02,12:03:01; DPB1*02:01:02; DQB1*02:02,03:01:01; DRB1*07,12 (PubMed=15748285).
CC   HLA typing: A*01:01:01:01,25:01; B*57:01:01,18:01; C*06:02,12:03; DPA1*01:03; DPB1*02:01:02; DRB1*07,12:01 (IPD-IMGT/HLA=11094).
CC   HLA typing: A*01:01:01,25:01:01; B*18:01:01,57:01:01; C*06:02:01,12:03:01 (DSMZCellDive=ACC-362).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (PubMed=17088437).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (PubMed=17088437).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC=CRL-1582; CCRID; CLS=300115; COG; Cosmic-CLP=905958; DSMZ=ACC-362; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=11416159; PubMed=19372543; PubMed=20922763; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11,12 (CLS=300115; DSMZ=ACC-362)
ST   CSF1PO: 11,12,13 (ATCC=CRL-1582; CCRID; COG; Cosmic-CLP=905958; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
ST   D13S317: 12,13 (ATCC=CRL-1582; CCRID; CLS=300115; COG; Cosmic-CLP=905958; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
ST   D13S317: 12,13,14 (DSMZ=ACC-362)
ST   D16S539: 11,14 (ATCC=CRL-1582; CCRID; CLS=300115; Cosmic-CLP=905958; DSMZ=ACC-362; JCRB=IFO50362; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
ST   D16S539: 11,14,15 (COG; JCRB=JCRB9031; PubMed=25877200)
ST   D18S51: 12,13,16,17,18 (DSMZ=ACC-362)
ST   D18S51: 12,13,17 (CLS=300115)
ST   D18S51: 13,16,17 (ATCC=CRL-1582; DOI=10.4172/2157-7145.S2-005)
ST   D18S51: 13,17 (CCRID; PubMed=19372543; PubMed=20922763; PubMed=25877200)
ST   D19S433: 14,15 (ATCC=CRL-1582; CCRID; DOI=10.4172/2157-7145.S2-005; DSMZ=ACC-362; PubMed=20922763; PubMed=25877200)
ST   D19S433: 14,15,16 (PubMed=19372543)
ST   D21S11: 27,28,29,30 (ATCC=CRL-1582)
ST   D21S11: 27,28,29,30,31 (COG; DOI=10.4172/2157-7145.S2-005; PubMed=25877200)
ST   D21S11: 28,29,30 (CLS=300115; DSMZ=ACC-362; PubMed=11416159)
ST   D21S11: 28,29,30,31 (CCRID; PubMed=19372543; PubMed=20922763)
ST   D2S1338: 23,24
ST   D3S1358: 14,16 (ATCC=CRL-1582; CCRID; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
ST   D3S1358: 15,16 (CLS=300115; DSMZ=ACC-362)
ST   D5S818: 11,12 (DSMZ=ACC-362)
ST   D5S818: 12 (ATCC=CRL-1582; CCRID; CLS=300115; COG; Cosmic-CLP=905958; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
ST   D5S818: 12,13 (PubMed=25877200)
ST   D7S820: 8,10 (DSMZ=ACC-362)
ST   D7S820: 8,10,11 (ATCC=CRL-1582; CCRID; CLS=300115; COG; Cosmic-CLP=905958; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763; PubMed=25877200)
ST   D8S1179: 9,13,14 (ATCC=CRL-1582; CLS=300115; DSMZ=ACC-362)
ST   D8S1179: 9,13,14,15 (PubMed=25877200)
ST   D8S1179: 9,14 (CCRID; COG; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
ST   D8S1179: 9,14,15 (PubMed=11416159)
ST   FGA: 21,22,23,24,25 (PubMed=25877200)
ST   FGA: 21,22,24,25 (DSMZ=ACC-362)
ST   FGA: 22,23,24,25 (ATCC=CRL-1582; COG; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=19372543; PubMed=20922763)
ST   FGA: 22,23,25 (CCRID)
ST   FGA: 22,24 (CLS=300115)
ST   FGA: 22,25 (PubMed=11416159)
ST   Penta D: 8,12,13 (CLS=300115; DSMZ=ACC-362)
ST   Penta D: 8,13 (ATCC=CRL-1582; PubMed=25877200)
ST   Penta E: 14,15 (DSMZ=ACC-362)
ST   Penta E: 14,15,16 (CLS=300115)
ST   Penta E: 14,16 (ATCC=CRL-1582; PubMed=25877200)
ST   TH01: 6,8
ST   TPOX: 8
ST   vWA: 16,17,18 (DSMZ=ACC-362)
ST   vWA: 17 (PubMed=11416159)
ST   vWA: 17,18 (ATCC=CRL-1582; CCRID; CLS=300115; COG; Cosmic-CLP=905958; JCRB=IFO50362; JCRB=JCRB9031; KCLB=21582; DOI=10.4172/2157-7145.S2-005; PubMed=20922763; PubMed=25877200)
ST   vWA: 17,18,19 (PubMed=19372543)
DI   NCIt; C9142; Adult T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_0624 ! MOLT-3
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 48
RX   CelloPub=CLPUB00447;
RA   Mulivor R.A., Suchy S.F.;
RT   "1992/1993 catalog of cell lines. NIGMS human genetic mutant cell
RT   repository. 16th edition. October 1992.";
RL   (In) Institute for Medical Research (Camden, N.J.) NIH 92-2011; pp.1-918; National Institutes of Health; Bethesda (1992).
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
RX   DOI=10.11418/jtca1981.15.4_211;
RA   Matsuo Y., Okochi A., Ariyasu T., Iimura E., Ohno T.;
RT   "Identification of cell lines with variable numbers of tandem repeat
RT   (VNTR) amplified by polymerase chain reaction.";
RL   Tissue Cult. Res. Commun. 15:211-219(1996).
RX   DOI=10.4172/2157-7145.S2-005;
RA   Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.,
RA   Hart R.P., Furtado M.R.;
RT   "STR profiling of human cell lines: challenges and possible solutions
RT   to the growing problem.";
RL   J. Forensic Res. 2 Suppl. 2:5-5(2011).
RX   PubMed=165156; DOI=10.1002/ijc.2910150217;
RA   Nilsson K., Ponten J.;
RT   "Classification and biological nature of established human
RT   hematopoietic cell lines.";
RL   Int. J. Cancer 15:321-341(1975).
RX   PubMed=1765142; DOI=10.1016/0014-5793(91)81402-t;
RA   Orita S., Saiga A., Takagi S., Tanaka T., Okumura K., Aono Y.,
RA   Hinuma Y., Igarashi H.;
RT   "A novel alternatively spliced viral mRNA transcribed in cells
RT   infected with human T cell leukemia virus type 1 is mainly responsible
RT   for expressing p21X protein.";
RL   FEBS Lett. 295:127-134(1991).
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K.D.,
RA   Vistica D.T., Hose C.D., Langley J., Cronise P., Vaigro-Wolff A.,
RA   Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
RX   PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x;
RA   Nakano A., Harada T., Morikawa S., Kato Y.;
RT   "Expression of leukocyte common antigen (CD45) on various human
RT   leukemia/lymphoma cell lines.";
RL   Acta Pathol. Jpn. 40:107-115(1990).
RX   PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990;
RA   Cheng J., Haas M.;
RT   "Frequent mutations in the p53 tumor suppressor gene in human leukemia
RT   T-cell lines.";
RL   Mol. Cell. Biol. 10:5502-5509(1990).
RX   PubMed=2846092; DOI=10.1182/blood.V72.5.1755.1755;
RA   Greenberg J.M., Gonzalez-Sarmiento R., Arthur D.C., Wilkowski C.W.,
RA   Streifel B.J., Kersey J.H.;
RT   "Immunophenotypic and cytogenetic analysis of Molt-3 and Molt-4: human
RT   T-lymphoid cell lines with rearrangement of chromosome 7.";
RL   Blood 72:1755-1760(1988).
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C.";
RL   Leuk. Res. 9:549-559(1985).
RX   PubMed=3335022;
RA   Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J.,
RA   Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.;
RT   "Feasibility of drug screening with panels of human tumor cell lines
RT   using a microculture tetrazolium assay.";
RL   Cancer Res. 48:589-601(1988).
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
RX   PubMed=4547172; DOI=10.1093/jnci/53.3.655;
RA   Huang C.C., Hou Y., Woods L.K., Moore G.E., Minowada J.;
RT   "Cytogenetic study of human lymphoid T-cell lines derived from
RT   lymphocytic leukemia.";
RL   J. Natl. Cancer Inst. 53:655-660(1974).
RX   PubMed=4567231; DOI=10.1093/jnci/49.3.891;
RA   Minowada J., Onuma T., Moore G.E.;
RT   "Rosette-forming human lymphoid cell lines. I. Establishment and
RT   evidence for origin of thymus-derived lymphocytes.";
RL   J. Natl. Cancer Inst. 49:891-895(1972).
RX   PubMed=6181032; DOI=10.1016/0198-8859(82)90037-4;
RA   Rabinowitz R., Weinstock J., Margalioth E.J., Ben-Bassat H.,
RA   Schlesinger M.;
RT   "Antigens specific for human T-lymphocytes detected by xenoantisera to
RT   HD-MAR cells: their differential expression on various T-cell lines.";
RL   Hum. Immunol. 4:219-228(1982).
RX   PubMed=6198871; DOI=10.18926/AMO/32400;
RA   Oda T., Watanabe S., Nakamura T.;
RT   "Type C virus particles produced in human T-cell lines derived from
RT   acute lymphoblastic leukemia and a leukemic T-lymphoid malignancy.";
RL   Acta Med. Okayama 37:529-533(1983).
RX   PubMed=6200433; DOI=10.1007/BF00364762;
RA   Brodsky F.M.;
RT   "A matrix approach to human class II histocompatibility antigens:
RT   reactions of four monoclonal antibodies with the products of nine
RT   haplotypes.";
RL   Immunogenetics 19:179-194(1984).
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
RX   PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5;
RA   Kawamura M., Ohnishi H., Guo S.-X., Sheng X.-M., Minegishi M.,
RA   Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M.,
RA   Sekiya T., Hayashi Y.;
RT   "Alterations of the p53, p21, p16, p15 and RAS genes in childhood
RT   T-cell acute lymphoblastic leukemia.";
RL   Leuk. Res. 23:115-126(1999).
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=11986953; DOI=10.1038/sj.leu.2402485;
RA   O'Donnell P.H., Guo W.-X., Reynolds C.P., Maurer B.J.;
RT   "N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to
RT   acute lymphoblastic leukemia cell lines, but not to non-malignant
RT   lymphocytes.";
RL   Leukemia 16:902-910(2002).
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11.1-11.8(2005).
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K.M., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P.J.,
RA   Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
RX   PubMed=22068913; DOI=10.1073/pnas.1111840108;
RA   Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J.,
RA   Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V.,
RA   Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R.,
RA   Ambudkar S.V., Gottesman M.M.;
RT   "Redefining the relevance of established cancer cell lines to the
RT   study of mechanisms of clinical anti-cancer drug resistance.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
RX   PubMed=22347499; DOI=10.1371/journal.pone.0031628;
RA   Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.;
RT   "Mass homozygotes accumulation in the NCI-60 cancer cell lines as
RT   compared to HapMap trios, and relation to fragile site location.";
RL   PLoS ONE 7:E31628-E31628(2012).
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L.,
RA   Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C.,
RA   Wilhelm M., Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20.1-20.13(2013).
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
RX   PubMed=24762992; DOI=10.7534/j.issn.1009-2137.2014.02.004;
RA   Ma X.-C., Liu C.-Y., Sun X.-J., He J.-J., Wan S.-G., Sun W.-L.;
RT   "Genetic characteristics of human acute lymphoblastic leukemia cell
RT   line Molt-4.";
RL   Zhongguo Shi Yan Xue Ye Xue Za Zhi 22:280-284(2014).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=26295583; DOI=10.1371/journal.pone.0135958;
RA   Vidyasekar P., Shyamsunder P., Arun R., Santhakumar R., Kapadia N.K.,
RA   Kumar R., Verma R.S.;
RT   "Genome wide expression profiling of cancer cell lines cultured in
RT   microgravity reveals significant dysregulation of cell cycle and
RT   microRNA gene networks.";
RL   PLoS ONE 10:E0135958-E0135958(2015).
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20.1-20.11(2016).
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
RX   PubMed=28569787; DOI=10.1038/cddis.2017.249;
RA   Kasai S., Furuichi Y., Ando N., Kagami K., Abe M., Nakane T., Goi K.,
RA   Inukai T., Saitoh S., Ohno S., Okazaki S., Nagano O., Saya H.,
RA   Sugita K.;
RT   "Inflammatory mediator ultra-low-molecular-weight hyaluronan triggers
RT   necrosis of B-precursor leukemia cells with high surface CD44
RT   expression.";
RL   Cell Death Dis. 8:e2857.1-e2857.11(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
RX   PubMed=32449352; DOI=10.1021/acs.jproteome.0c00254;
RA   Cao X.-W., Khitun A., Na Z.-K., Dumitrescu D.G., Kubica M., Olatunji E.,
RA   Slavoff S.A.;
RT   "Comparative proteomic profiling of unannotated microproteins and
RT   alternative proteins in human cell lines.";
RL   J. Proteome Res. 19:3418-3426(2020).
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).